Teva Pharmaceutical Industries Ltd. has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.
The settlement was disclosed on Tuesday in papers filed in federal court in Connecticut. The company did not admit to wrongdoing.
